Skip to content

Study the relationship between UGT1A1, MTHFR gene polymorphism and colorectal cancer chemotherapy sensitivity

Study the relationship between UGT1A1, MTHFR gene polymorphism and colorectal cancer chemotherapy sensitivity

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-CCH-08000114
Enrollment
Unknown
Registered
2008-02-21
Start date
2007-10-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colonic and rectal cancer

Interventions

UGT1A1 genotype group:5-FU/CF/CPT-11
MTHFR genotype group:5-FU/CF/CPT-11

Sponsors

Jiangsu Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. histopathology confirmed advanced colorectal cancer; 2. without chemotherapy (or non-CPT-11 after adjuvant chemotherapy program in progress) in patients with advanced; 3. have failed chemotherapy (not used CPT-11) in patients with advanced; 4. there are measurable lesions (diameter: General CT >= 20mm; spiral CT >=10mm), or can not be measured in patients with the disease (Observer OS); 5. age >= 18 years old; 6. ECOG status of acts score (see Appendix I) =3 months; 8. the results of laboratory tests required to meet the following criteria: blood: ANC >=1.5*10^9/L, PLT >=80*10^9 /L, Hb >=90g/L; renal function: Cr <1.25*N; liver function: no cases of liver metastases: total bilirubin <=1.25 *N, ALT <=1.5*N; there are cases of liver metastases: TBil <= 1.50*N, ALT<=3.0*N; 10. rehabilitation treatment from the people at the end of chemotherapy 4 weeks or more; 11. normal electrocardiogram.

Exclusion criteria

Exclusion criteria: 1. in the past has been the treatment of CPT-11; 2. history of chronic diarrhea; 3. inflammatory bowel disease or a history of extensive removal of the colon> 50% or extensive small bowel resection with chronic diarrhea; 4. in the past have received partial abdominal or pelvic radiation Treatment; 5. intestinal obstruction or incomplete intestinal obstruction; 6. serious peripheral neuropathy; 7. brain or meningeal transfer; 8. major organ failure; 9. beyond the control of severe infections; 10. or pregnancy Breast-feeding women; 11. at the same time the use of other experimental drugs or participate in other clinical trials; 12. serious heart and lung failure.

Design outcomes

Primary

MeasureTime frame
Fatality rate;Survival tim;

Secondary

MeasureTime frame
Blood picture;ECOG score;Renal and lver function;

Countries

China

Contacts

Public ContactJifeng Xu
laogao03@yahoo.com.cn+86 025 13905181246

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026